您即将离开沛嘉医疗中文官网。
您刚才点击了进入另一网站的链接。如果继续,您可能会进入由第三方运行的网站。 我们不负责对非沛嘉医疗中文官网上的内容进行审核与管控,亦不会对您在非沛嘉医疗中文网上的任何商业交易或事物承担任何责任。您使用其他网站时,必须遵循该网站的使用条款及隐私声明。 其他网站上的部分产品和信息可能并未在您所在地区或国家获得批准。
取消
继续
Brief News on Innovation
Company News Brief News on Innovation
China’s Independently Developed TEER GeminiOne Gained Further Evidence: Comparative Hemodynamic and Biomechanical Evaluation
2025-07-02 13:44:49

In July 2025, Dr. Jianfeng Chen, leading the R&D team at Peijia Medical, collaborated with Prof. Saibal Kar from Los Robles Regional Medical Center (USA), Prof. Zhaoming He from Texas Tech University, and Dr. Dongyang Xu from Worcester Polytechnic Institute published a comparative analysis of the hemodynamic and biomechanical performance of Peijia Medical’s GeminiOne mitral valve edge-to-edge repair device. The study used in vitro DMR and FMR models to evaluate the immediate MR reduction and leaflet grasping stability of GeminiOne (GEM) versus MitraClip (MC).

裁剪旋转.jpeg

Results showed that GEM0626 and MC XTW provided comparable MR reduction. However, GEM0626 demonstrated superior leaflet stability, requiring greater dislodgement force—suggesting potential for better long-term clinical outcomes.

For more information, please visit: https://mp.weixin.qq.com/s/Dk_W9O7Q5_Zy-JRLmCxy3g


Top